Nitric oxide is a short-lived signalling molecule involved in blood vessel relaxation, endothelial function and other physiological pathways. This collection brings together foundational research, human clinical trials and systematic reviews of dietary nitrate, beetroot, L-arginine and L-citrulline, alongside the published Nitralis study. Each paper distinguishes its study design, measured outcomes and limitations; changes in nitric oxide-related biomarkers do not, by themselves, establish clinical benefits.
Thirty-eight-trial pooled exercise outcome; potential publication bias and little evidence of effect in highly trained athletes.
Systematic review of placebo-controlled trials with GRADE assessment; certainty for clinic systolic BP effect low.
Double-blind crossover placebo-controlled trial measuring blood pressure; neutral finding despite large biomarker changes.
Broad narrative review covering NO synthase biology, NO signaling, and biomedical NO-delivery platforms (donors, nanoparticles, hydrogels) across wound healing, antibacterial, cardiovascular, and oncology applications; synthesizes preclinical/in vitro literature rather than presenting original data.
Clinically-oriented review (Critical Care Clinics) synthesizing the pathophysiology of endothelial NO signaling loss in sepsis, ARDS, and critical illness, and clinical strategies (e.g., inhaled NO, NO donors) to restore endothelial function. Mechanistic/clinical synthesis rather than original primary data.
Rigorous preclinical bioassay study that definitively established EDRF as a genuine humoral (diffusible) substance rather than a direct nerve or contact-mediated effect. However, its central claim about EDRF's chemical identity (an unstable carbonyl-containing compound, not a free radical or lipoxygenase product) was superseded three years later when EDRF was conclusively identified as nitric oxide; historically important for methodology and for establishing EDRF's humoral nature, but its specific chemical-identity conclusion is now known to be incorrect.
Narrative review synthesizing mechanistic and preclinical literature on NO signaling (S-nitrosation, nitration, cGMP-dependent/independent pathways) in cardiovascular, neurodegenerative, and immune/oncological aging processes. Not primary experimental data; value lies in mechanistic synthesis and identification of NO-based diagnostic/therapeutic strategies for age-related disease, drawing on 280 primary and review sources.
Landmark preclinical mechanistic study, published concurrently with the Ignarro et al. PNAS paper, that directly demonstrated NO release from cultured endothelial cells accounts for EDRF's biological activity; a cell-culture and bioassay study, not a human trial, but foundational to all subsequent cardiovascular NO research.
Landmark preclinical mechanistic study directly establishing the chemical identity of EDRF as nitric oxide using isolated bovine artery/vein bioassay and chemical detection methods; not a human trial, but foundational translational mechanistic evidence underlying all downstream cardiovascular NO biology and pharmacology.
Single-author Nobel Prize lecture synthesizing the author's own primary discoveries plus a comprehensive body of corroborating human and animal vascular biology research; not a primary RCT but an authoritative expert synthesis by a Nobel laureate directly responsible for the core discoveries.
Sourcedoi:10.1002/(SICI)1521-3773(19990712)38:13/14<1882::AID-ANIE1882>3.0.CO;2-VPMID 34182699
Narrative historical review by one of the discoverers of NO's vascular signaling role, synthesizing two decades of the author's own mechanistic and translational research program on NO/cGMP in the cardiovascular system.
SourcePMID 12512688
Single prospective, randomized, placebo-controlled human clinical trial (n=61) in women with preeclampsia, directly measuring blood pressure and NO biomarker outcomes.
Authoritative narrative clinical pharmacology review by cardiology and sexual-medicine specialists, synthesising an extensive human clinical trial and pharmacovigilance evidence base underlying a well-established, guideline-level drug contraindication. Full-text review confirms the manuscript was sponsored by Pfizer Limited (maker of sildenafil/Viagra), with editorial assistance also funded by Pfizer, and that most of the eight authors disclose consulting, employment, speaker, advisory-board, or shareholding relationships with Pfizer and/or other PDE5-inhibitor or cardiovascular drug manufacturers. This funding and the extensive author COI are material and are disclosed in full below. They do not undermine the specific contraindication itself, which is independently confirmed in drug labelling and cardiology guidelines worldwide and predates this review, but they should be weighed when reading this paper's framing and recommendations (e.g., its washout-interval guidance) rather than treating it as an independent source.
Short editorial commentary on Ishinoda et al. (J Atheroscler Thromb 2023; 30:1364-1375) synthesizing the L-arginine/L-ornithine ratio and eNOS/arginase axis in endothelial dysfunction; expert opinion, no primary or systematic-review data.
Narrative physiological review synthesizing human and mechanistic evidence on sex differences in vascular ageing and nitric oxide bioavailability; not a systematic review, but authored by a research group with an extensive primary-study record in this specific area. Full-text review confirms funding was exclusively from NIH grants and US Department of Veterans Affairs research support, with no conflicts of interest declared by any author - a genuinely independent evidence base for this article's sex-differences claims.
Sourcedoi:10.1152/ajpheart.00392.2023PMID 37921669PMC11208002
Large (n=500), well-designed cross-sectional human physiological study directly measuring endothelium-dependent flow-mediated dilation (a validated marker of nitric oxide-dependent endothelial function) against cardiovascular risk factors. Not a randomised controlled trial and cannot establish causation or predict future clinical events, but it is a foundational, frequently-cited human dataset (rather than animal or in-vitro data) establishing that smoking, age, male sex and vessel size are independently associated with impaired endothelium-dependent dilation, with risk factors interacting rather than acting purely additively.
GRADE-informed three-level meta-analysis of randomized citrulline malate exercise trials; pooled effects small and certainty low to very low.
Randomized double-blind crossover human pharmacokinetic study; plasma arginine response cannot be equated to superior clinical outcomes.
Sourcedoi:10.1111/j.1365-2125.2007.02990.xPMID 17662090PMC2291275
Narrative review of predominantly preclinical evidence — rodent, avian, fish, and invertebrate models — with only speculative extrapolation to human cognitive health.
SourcePMID 21623030PMC3121276
Narrative literature review of type 2 diabetes macrovascular complications (coronary heart disease, cerebrovascular disease, peripheral artery disease), not a systematic review or meta-analysis. Built from the PubMed abstract only because the full text could not be located despite request; methodological detail beyond the abstract is unverified and should be revisited if the full text becomes available.
GRADE-assessed dose-response systematic review and meta-analysis of randomized clinical trials; population and intervention heterogeneity remain important.
Sourcedoi:10.1186/s12937-025-01114-8PMID 40128734PMC11931885
Randomized phase 2 trial with home, clinic and ambulatory BP endpoints; moderate sample, 4-week intervention.
Sourcedoi:10.1161/HYPERTENSIONAHA.114.04675PMID 25421976PMC4288952
Narrative review synthesising a substantial body of human RCT evidence on dietary nitrate and exercise, from an author whose own laboratory generated many of the primary studies discussed.
Umbrella synthesis of 20 systematic reviews; most source reviews assessed low/critically low method quality.
Sourcedoi:10.1007/s40279-025-02194-6PMID 40085422PMC12106159
Systematic review and meta-analysis of performance trials; outcome and formulation specificity needed.
Six-trial meta-analysis, sprint tests varied and only selected sprint outcomes improved.
Dose-response synthesis of randomized placebo-controlled studies; participant and dosing heterogeneity limits individual prediction.
Ten-trial meta-analysis, with arginine-only and combination formulations and moderate heterogeneity.
Meta-analysis of only five clinical interventions; small trials and nonuniform outcome measures reduce certainty.
Eight small randomized trials; study overlap with Mirenayat 2018 prevents treating the two syntheses as independent evidence.
SourcePMID 30788274PMC6369322
Randomized crossover human trial documenting neutral vascular endpoints despite changes in nitrate metabolism.
Laboratory validation study with only twenty participants; evaluated specific commercial strips rather than Nitralis trial strips.
Sponsor-funded, industry-authored randomized pilot using semi-quantitative salivary test strips and no hard or validated vascular endpoint.
Small randomized crossover human validation study comparing nitrite strips with quantitative reference assays.
Narrative toxicological/epidemiological review, not a systematic review or meta-analysis - no pre-registered protocol, systematic search strategy, or formal risk-of-bias assessment. Full-text review confirms the review was funded by the American Meat Institute Foundation (a meat-industry trade body with a direct commercial interest in nitrite's safety profile, since nitrite is used to cure processed meat) and that the lead author discloses a financial interest in a nitric-oxide-related commercial products company. This funding and competing interest do not by themselves invalidate the animal toxicology data reviewed, but they are a material reason to weigh this review's reassurance alongside independently funded evidence, such as Said Abasse et al. 2022's systematic review and meta-analysis, rather than relying on it in isolation.
Systematic review and meta-regression/meta-analysis (PRISMA/MOOSE methodology) of 41 observational epidemiological studies across 13 cancer sites; strongest available human evidence synthesis on this question, though built on observational (non-RCT) data with residual confounding risk typical of nutritional epidemiology.
Randomized placebo-controlled double-blind crossover intervention in young versus older adults; short intervention and surrogate endpoints.
Randomized crossover analysis of an overlapping 15-person cohort; microbiome endpoints are not independent cardiovascular trials.
Controlled sequential before/after intervention in 19 people; fixed sequence and small sample limit causal certainty.
Sourcedoi:10.1016/j.freeradbiomed.2012.11.013PMID 23183324PMC3605573
Small but randomized crossover of antibacterial mouthwash versus water; short duration and surrogate endpoints.
Narrative review synthesising human RCT and mechanistic evidence across multiple supplement categories (L-arginine, L-citrulline, dietary nitrate/beetroot juice, glycine propionyl-L-carnitine, 2-nitroxy ethyl 2-amino-3-methylbutanoate); reasonable synthesis but non-systematic methodology.
Sourcedoi:10.15167/2421-4248/jpmh2022.63.2S3.2766PMID 36479475PMC9710401
Network meta-analysis (Bayesian mixed-treatment comparison) of 37 randomised controlled trials totalling 2,983 patients with intermittent claudication, directly comparing best medical therapy, supervised exercise therapy, angioplasty, and angioplasty plus exercise. This is high-quality synthesised evidence from randomised human trials, the strongest evidence tier available for a clinical intervention question, though limited by the absence of patient-level data and by unblinded, non-sham-controlled component trials, an inherent limitation of exercise/procedural interventions.
Controlled human physiological experiment (pre/during/post measurement design) in 20 healthy adults directly measuring vascular function (flow-mediated dilation, pulse wave velocity, microvascular blood velocity) before and after 3 hours of uninterrupted sitting. Real human data with objective vascular endpoints, though a small single-session study rather than a randomised trial or long-term outcome study. Built from the PubMed abstract only because the full text could not be located despite request.
Small, single-blind sequential placebo-then-treatment study, vulnerable to sequence and expectation effects.
Small six-trial meta-analysis restricted to sodium nitrate; beetroot-juice trials explicitly excluded.
Randomized double-blind trial in a clinically important high-risk patient population, stopped early over mortality concerns.
